![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bharat Biotech’s Covaxin Vaccine Demonstrates Strong Antibody Response
Bharat Biotech’s Covaxin Vaccine Demonstrates Strong Antibody Response
![Vaccine needle](https://www.fdanews.com/ext/resources/test/Drug-Images4/Vaccine-needle-bottle.gif?t=1596243581&width=430)
March 11, 2021
Bharat Biotech’s Covaxin (BBV152), the first successful COVID-19 vaccine developed in India, showed high levels of antibody response and no serious side effects in a phase 2 study, researchers reported in The Lancet.
Last week, the company reported that the vaccine demonstrated an 81 percent efficacy in preventing symptomatic COVID-19 in an interim analysis from a 25,800-participant phase 3 trial.
The two-dose vaccine can be stored at standard refrigeration temperatures of 35.6 to 46.4 degrees Fahrenheit, so it presents fewer logistical hurdles than messenger RNA-based vaccines that must be stored ultra-cold.
Upcoming Events
-
21Oct